A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction.

@article{Govier2003AMR,
  title={A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction.},
  author={Fred E. Govier and Axel-Juerg Potempa and Joel D. Kaufman and Jonathan Denne and Pavel Kovalenko and Sanjeev B. Ahuja},
  journal={Clinical therapeutics},
  year={2003},
  volume={25 11},
  pages={
          2709-23
        }
}
BACKGROUND Tadalafil is a phosphodiesterase 5 (PDE5) inhibitor approved in >30 countries for the treatment of erectile dysfunction (ED). It has been shown to improve erectile function compared with placebo in Phase III studies, but clinical experience comparing tadalafil with the PDE5 inhibitor sildenafil citrate is lacking. OBJECTIVE This study compared patient preference for tadalafil 20 mg or sildenafil 50 mg during initial treatment for ED. It also compared the tolerability of the 2… CONTINUE READING
Highly Cited
This paper has 41 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations